From: Understanding covid-19 outcomes among people with intellectual disabilities in England
 | No ID | ID | p value |
---|---|---|---|
N in the analysis dataset | 8408930 | 45820 | Â |
Age at covid-19 (median [IQR]) | 41.79 [29.95, 54.99] | 40.79 [27.99, 57.81] |  < 0.001 |
Female (%) | 54.0 | 42.2 |  < 0.001 |
Ethnicity (%) |  |  |  < 0.001 |
 White | 82.8 | 87.7 |  |
 Asian | 9.2 | 6.5 |  |
 Black | 3.7 | 3.1 |  |
 Mixed | 1.9 | 1.6 |  |
 Other | 2.4 | 1.0 |  |
IMD decile (mean (SD)) | 5.36 (2.85) | 4.59 (2.74) |  < 0.001 |
Percent vaccinated at least once | 50.8 | 43.3 |  < 0.001 |
Vaccine, if any: (%) |  |  |  < 0.001 |
 AstraZeneca | 41.4 | 58.7 |  |
 Moderna | 6.6 | 2.9 |  |
 Pfizer | 51.9 | 38.4 |  |
Percent affected by multimorbidity* | 13.1 | 32.4 |  < 0.001 |
Count of Long-Term Conditions (mean (SD))** | 1.32 (3.18) | 2.60 (4.20) |  < 0.001 |
Percent affected by polypharmacy*** | 20.9 | 55.6 |  < 0.001 |
Count of prescription medications (mean (SD)) | 2.70 (3.84) | 6.28 (5.07) |  < 0.001 |